9 Myths About Compounded Bioidentical Hormones That Women Need to Stop Believing
When the compounded BHRT world found me, it was seductive — the language of 'natural,' 'personalized,' and 'what your body actually needs' felt like someone finally understood. It took digging into the actual research to realize how much of that language was marketing dressed up as medicine, and that some genuinely good options had been sitting in plain sight all along.
Learn more about Rose →Myth: Compounded hormones are 'natural' and FDA-approved hormones are synthetic
Both compounded and many FDA-approved bioidentical hormones are derived from the same plant sources — typically wild yam or soy — and processed into molecularly identical hormones in a lab. The word 'natural' in this context is a marketing term, not a regulatory or chemical distinction. Estradiol patches, gels, and sprays that are FDA-approved are structurally identical to the estradiol used in compounded preparations.
Myth: 'Bioidentical' is exclusive to compounded hormones
The term bioidentical simply means the hormone molecule is identical in structure to the one the human body produces — and dozens of FDA-approved products already meet that definition. Estradiol (as patches, gels, sprays, and vaginal rings) and micronized progesterone (Prometrium and its generics) are all FDA-approved and bioidentical. Compounding pharmacies do not have a trademark on the concept.
Myth: Compounded hormones are safer because they're 'personalized'
Compounded preparations are not tested for safety or efficacy as finished products — the FDA does not review or approve them, meaning there is no independent verification of dose accuracy, sterility, or absorption consistency. Studies have found significant variability in compounded hormone potency, with some preparations delivering far more or less hormone than labeled. FDA-approved products undergo rigorous pharmacokinetic testing to confirm that what's on the label is what the body actually receives.
Myth: Salivary hormone testing makes compounded BHRT more precise
Salivary hormone testing is frequently used to 'customize' compounded BHRT prescriptions, but it is not a validated method for guiding hormone therapy decisions. Salivary levels fluctuate dramatically throughout the day and are heavily influenced by what a woman has recently eaten, drunk, or applied to her skin. Major menopause societies — including the Menopause Society (formerly NAMS) — do not recommend salivary testing as a basis for prescribing hormone therapy.
Myth: Compounded progesterone cream is equivalent to oral micronized progesterone
Topical progesterone cream is one of the most commonly sold compounded products, often promoted as a gentler alternative to oral progesterone — but the evidence shows it does not adequately protect the uterine lining. Studies have found that transdermal progesterone produces inconsistent and generally insufficient serum levels to provide endometrial protection in women who still have a uterus. Women using estrogen therapy who have a uterus need a progestogen that reliably opposes estrogen's effect on the endometrium, and progesterone cream has not demonstrated this reliably.
Myth: Compounded tri-estrogen (Biest or Triest) is superior to standard estradiol
Biest (a combination of estradiol and estriol) and Triest (estradiol, estrone, and estriol) are promoted as more 'complete' and balanced than standard estradiol therapy — but there is no clinical evidence supporting this claim. The body naturally converts estradiol into estriol and estrone as needed; supplementing all three simultaneously does not mimic the body's natural hormonal environment more closely. No randomized controlled trials have shown combination estrogen preparations to be more effective or safer than estradiol alone.
Myth: Compounded BHRT has no cancer risk because it's 'natural'
The biological activity of a hormone depends on its molecular structure — not its origin or how it was compounded. Estradiol, whether compounded or FDA-approved, stimulates estrogen receptors in the same way, meaning the same considerations around breast tissue and endometrial health apply to both. There is no clinical evidence that compounded hormones carry a lower breast cancer risk than FDA-approved equivalents at the same doses, and the assumption that 'natural' confers protection is not supported by endocrinology.
Myth: Women can only get truly individualized hormone therapy through compounding
FDA-approved hormone therapy already offers a meaningful range of doses, delivery methods, and formulations — patches, gels, sprays, rings, tablets, and vaginal preparations — that allow real clinical flexibility. A knowledgeable menopause specialist can titrate dose and delivery method to match a woman's symptoms and response using approved products. True individualization comes from careful clinical assessment and follow-up, not from a compounding prescription based on a single saliva test.
Myth: The medical establishment dismisses compounded BHRT because of Big Pharma bias
Major menopause societies — including the Menopause Society, the British Menopause Society, and the International Menopause Society — are skeptical of compounded BHRT not because of pharmaceutical pressure, but because unregulated preparations carry documented risks including inconsistent dosing, contamination, and a lack of long-term safety data. Their concern is a patient safety position, grounded in the same framework that governs any medical intervention. That said, compounding does have a legitimate role for women with genuine allergies to excipients in standard products or specific needs not met by approved formulations — a nuance that responsible clinicians acknowledge.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.